A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Pandurangan, A.
- Dissolution Method Development and Validation for Combination Dosage Form of Telmisartan and Nebivolol hydrochloride Tablets using UV Spectrophotometric Method
Authors
1 M M College of Pharmacy, Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, IN
2 M M University, Solan, Himachal Pradesh, IN
3 Reginal Drugs Testing Laboratory, Ballari, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 2742-2747Abstract
The combination tablets dosage form of Telmisartan and Nebivolol hydrochloride dissolution method was developed by UV spectrophotometer and validated was according to the ICH guidelines. The any official method of this combination drugs was not available. In this proposed method two commercial brands of drug was used. The simultaneous estimation of Telmisartan and Nebivolol hydrochloride was performed in this proposed method which includes to solving of simultaneous equation. The wavelength of Telmisartan 296nm and 281nm of Nebivolol hydrochloride was used in this simultaneous equation. The dissolution mediums such as 0.1N HCl, phosphate buffer, SFG (without enzyme) at various ph was used in this method. The selected proposed dissolution method was SFG dissolution media (without enzyme) 900 ml, speed 75 rpm, USP type II apparatus and temperature at 37 ± 0.5°C and drug release than 85% within 45mints. The optimized proposed method easy to handle and commercially used for the routine quality control checking of Telmisartan and Nebivolol hydrochloride pharmaceutical combine tablets dosage form.Keywords
Telmisartan, Nebivolol Hydrochloride, Simultaneous Equation, Dissolution, Validation, ICH Guidelines.
References
- Dressman J, Kramer J. Pharmaceutical dissolution testing. Taylor and Francis group, editors. Dissolution testing: Guidance for industry. New York: Marcel Dekker; 352 – 53, 2005.
- Lesson LJ. Invitro/in vivo correlations. Drug Information Journal 1995; 29:903-915.
- Vaucher LC. Development and validation of a dissolution test for telithromycin in coated tablets. Quimica Nova 2009, 32(5):1–5.
- Harika, CH, Raja Jaya Rao Y, Gousia Parvin SK, Siva Shankar Sastry CH. Formulation and evaluation of Nebivolol tablets. International Journal of Pharmaceutical Archive 2013, 2(11): 251-258.
- Judy, WMC, Nebivolol: A third-generation _-blocker for hypertension. Cli. Therapeutics, 2009, 31(3):447-62.
- Budavari, S. O’Neil, M.J. Smith, A, Heckelman, PE. , Ed. The Merck Index, Mary Adele 13th edition published by Merck Research Lab, Division of Merck and Co, White house station, NJ, USA, 148.2001.
- Dressman JB, Amidon GL, Reppas C, Shah VP, Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms, Pharmaceutical Research 1998, 15(1):11–22.
- Sweetman SC. Martindale, the Complete Drug Reference. 34th edition. The Pharmaceutical Press, Great Britain 2002: 48-76.
- Beckett AH, Stenlake JB. Practical pharmaceutical chemistry. Fourth edition part II. New York: Continuum international publishing group 284-286, 2001.
- Khan F, Lohiya RT, Umekar MJ. Development of UV Spectrophotometric method of the simultaneous estimation of Meloxicum and Paracetamol in Tablet by simultaneous Equation, Absorbance ration and Absorbance Correction method. International Journal of Chem Tech Research, 2010: 2 (3).
- Garcia CV, Paim CS. Steppe M, Schapoval, EES. Development and validation of a dissolution test for rabeprazole sodium in coated tablets. Journal of Pharmaceutical and Biomedical Analysis 2006, 641(3): 833–837.
- International Conference on Harmonization Q2 (R1). Draft Guideline on Validation of Analytical Procedures: Definitions and Terminology, Federal Register. 60, 11260.
- Patel PA, Patravale. VB, Commercial Telmisartan Tablets: A Comparative Evaluation with Innovator. Brand Micardis, International Journal of Pharma Sciences and Research, 2010, 1 (8): 282–292.
- Shohin IE, Kucinich JI, Ramensakya GV, Vasilenko GF, Evaluation of In Vitro Equivalence for Drugs Containing BCS Class II Compound Ketoprofen, Dissolution Technologies 2011, 18 (1): 26–29.
- Gowthamarajan K, Singh SK, Dissolution Testing for Poorly Soluble Drugs: A Continuing Perspective, Dissolution Technologies 2010, 17(3): 24–32.
- The United States Pharmacopeia and National Formulary USP 27–NF 24, the United States Pharmacopeial Convention, Inc.: Rockville, MD, 2007.
- Current Research in Neuropathology and Pharmacotherapy of Alzheimer’s Disease:A Review
Authors
1 Research Scholar, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, IN
2 Associate Professor, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, IN
3 Professor, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, IN
4 Research Associate, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, IN
5 Professor, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, IN
Source
Indian Journal of Public Health Research & Development, Vol 11, No 1 (2020), Pagination: 334-339Abstract
Background: Alzheimer’s disease (AD), a category of neurological degeneration generally seen in elderly people which is reflected by memory loss and affecting daily living activities.
Method: The data has been accessed from scopus, pubmed, science-direct and google-scholar which is included in this article.
The literature provide the information about pathological alterations of Alzheimer disease emphasizing on formation of neuritic plaques, beta amyloid protein, neurofibrillary tangle and also updates therapeutics used in Alzheimer’s disease including cholinesterase inhibitors, ACE inhibitors, NMDA receptor antagonists, secretase inhibitors and anti-inflammatory drugs, herbal drugs and other naturals.
Results: The research on neuropathology and diagnosis of Alzheimer’s disease are determinants of this study. The pathophysiology, diagnosis using biomarkers and therapeutics of disease has been summarized.
Conclusion: The aim of this review paper is to focus on how diagnosis and pharmacotherapy of Alzheimer’s disease useful for researchers engaged in the experimental research.
Keywords
Alzheimer’s Disease, β-amyloid Precursor Protein, Neurofibrillary Tangles, Acetylcholinesterase Inhibitors, Secretase Inhibitors, Biomarkers.- Current Research in Neuropathology and Pharmacotherapy of Alzheimer’s Disease:A Review
Authors
1 Research Scholar, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, IN
2 Associate Professor, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, IN
3 Professor, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, IN
4 Research Associate, Department of Pharmacology, All India Institute of Medical sciences, New Delhi, IN
5 Professor, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, IN
Source
Indian Journal of Public Health Research & Development, Vol 11, No 2 (2020), Pagination: 427-432Abstract
Background: Alzheimer’s disease (AD), a category of neurological degeneration generally seen in elderly people which is reflected by memory loss and affecting daily living activities.
Method: The data has been accessed from scopus, pubmed, science-direct and google-scholar which is included in this article. The literature provide the information about pathological alterations of Alzheimer disease emphasizing on formation of neuritic plaques, beta amyloid protein, neurofibrillary tangle and also updates therapeutics used in Alzheimer’s disease including cholinesterase inhibitors, ACE inhibitors, NMDA receptor antagonists, secretase inhibitors and anti-inflammatory drugs, herbal drugs and other naturals.
Results: The research on neuropathology and diagnosis of Alzheimer’s disease are determinants of this study. The pathophysiology, diagnosis using biomarkers and therapeutics of disease has been summarized.
Conclusion: The aim of this review paper is to focus on how diagnosis and pharmacotherapy of Alzheimer’s disease useful for researchers engaged in the experimental research.